LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "corporate appointments" as a keyword



P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results

Sign Up to like & get
recommendations! Published in 2020 at "Rheumatology"

DOI: 10.1093/rheumatology/keaa111.205

Abstract: Filgotinib (FIL) is an oral, potent, selective Janus kinase 1 inhibitor that has shown good efficacy and was well tolerated for treatment of rheumatoid arthritis (RA). The objective of this study was to evaluate efficacy… read more here.

Keywords: gilead sciences; shareholder; sciences inc; gilead ... See more keywords

O18 Integrated molecular analysis of systemic sclerosis skin and blood shows significant differences between major autoantibody subgroups

Sign Up to like & get
recommendations! Published in 2021 at "Rheumatology"

DOI: 10.1093/rheumatology/keab246.017

Abstract: Background/Aims  The major antinuclear autoantibodies of systemic sclerosis (SSc) associate with different skin score trajectories and risk of internal organ manifestations. To elucidate molecular differences between ANA-defined subgroups, we utilised the prospective BIOPSY cohort of… read more here.

Keywords: appointments employee; corporate appointments; skin; early dcssc ... See more keywords

OA04 Efficacy and safety of nipocalimab in patients with moderate to severe active rheumatoid arthritis: the multicenter, randomised, double-blinded, placebo-controlled phase 2a IRIS-RA study

Sign Up to like & get
recommendations! Published in 2024 at "Rheumatology"

DOI: 10.1093/rheumatology/keae163.004

Abstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with autoantibodies. Despite the use of targeted therapies, up to half of patients fail to achieve remission or low disease activity (LDA). Anti-citrullinated protein antibodies (ACPAs),… read more here.

Keywords: corporate appointments; janssen research; research development; employee janssen ... See more keywords

OA25 Efficacy and safety of nipocalimab, an anti-FcRn monoclonal antibody, in primary Sjogren’s disease: results from a Phase 2, multicenter, randomized, placebo-controlled, double-blind study (DAHLIAS)

Sign Up to like & get
recommendations! Published in 2025 at "Rheumatology"

DOI: 10.1093/rheumatology/keaf142.025

Abstract: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by the presence of specific autoantibodies (AAb) and lymphocytic infiltration of exocrine glandular tissues. Nipocalimab is an anti-neonatal Fc receptor (FcRn) monoclonal antibody that reduces… read more here.

Keywords: corporate appointments; johnson; johnson shareholder; johnson johnson ... See more keywords